Antithrombotics Pathophysiological Rationale for Pharmacological Interventions

1. Platelet activation and aggregation: rationale for combining antithrombotic drugs.- 2. Role of nitric oxide in endothelial cell - platelet interactions.- 3. Platelets and megakaryocytes in vascular disease.- 4. Thrombosis in relation to atherosclerosis.- 5. Pharmacological inhibition of the ADP-GP IIb/IIIa-fibrinogen pathway of platelet aggregation.- 6. Calcium fluxes in platelets and endothelial cells, mechanisms and functional significance.- 7. Inhibition of platelet function by cyclic nucleotides and cyclic nucleotide-dependent protein kinases.- 8. Pharmacological modification of platelet-derived cyclooxygenase product formation and its consequences for platelet-vessel wall interactions.- 9. Antithrombotics and the lipoxygenase pathway.- 10. Pathological expressions of platelet-vessel wall interactions: implications of serotonin.- 11. The involvement of PAF in thrombotic events.- 12. Prostaglandins and -analogs in the treatment of platelet-vessel wall interaction.- 13. Adjuvant agents to enhance and sustain reperfusion with t-PA: studies in experimental dog models.- 14. Effect of dietary marine lipids on (anti-)thrombotic mechanisms.